Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Managing rheumatoid arthritis during COVID-19

The outbreak of coronavirus in the world has led to an uncertainty about treatment of patients with autoimmune disorders because of their weakened immune system coupled with immunosuppressive agents they take which predisposes them to a host of infections. Data on COVID-19 patients with underlying rheumatological diseases has been emerging mostly in the form of small case series and one global registry. From these data, it seems like our patients, although immunosuppressed, are not particularly susceptible to the coronavirus infection and if infected, do not have significantly worse outcomes than other patients. In fact, drugs like hydroxychloroquine, dexamethasone, and tocilizumab have been studied for treatment of COVID-19. However, this is only preliminary data, and since a few parts of the world are still grappling with the pandemic at its peak, we need to be equipped on how to protect and manage our immunosuppressed patients. Published evidence to guide treatment decisions are lacking and doubts regarding continuation and initiation of immunosuppressants remain. Rheumatoid arthritis (RA) is the most common immune-mediated disorder in COVID-19 patients, and in this review, we discuss how the commonly used drugs in RA alter the patients' susceptibility to this infection. The review also summarizes the recommendations from the major bodies on how to manage this disease in these times. Key Points • Patients on immunosuppressive medications are not found to be at a greatly increased risk of acquiring COVID-19 infection. • Patients doing well on a stable dose of steroid and/or Disease-Modifying Antirheumatic Drugs (DMARDs) should be allowed to continue the same unless they get infected in which case, temporary stoppage of methotrexate and leflunomide may be considered. • Initiation of high-dose steroids, DMARDs, and biologics, if the clinical situation demands so, can be done. • Maintenance biologic therapy for stable patients should be individualized by the treating... Full description

Year of Publication: 2020
Contained in: Clinical rheumatology Vol. 39, No. 11 (2020), p. 3237-3244
All journal articles: Search for all articles in this journal
Language: English
Contributors: Roongta, Rashmi | Author
Ghosh, Alakendu
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Journal Article
Management
Review
Rheumatoid arthritis
Treatment
Additional Keywords: *Coronavirus Infections
*Pandemics
*Pneumonia, Viral
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Arthritis, Rheumatoid
Betacoronavirus
Biological Products
Deprescriptions
Disease Management
Glucocorticoids
Humans
Tumor Necrosis Factor Inhibitors
ISSN: 1434-9949
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 23.10.2020
Date Revised 23.10.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32892311
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s10067-020-05358-z
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04768nma a2200781 c 4500
001 NLM315597941
003 DE-601
005 20201024213544.0
007 cr uuu---uuuuu
008 200907s2020 000 0 eng d
024 7 |a 10.1007/s10067-020-05358-z  |2 doi 
028 5 2 |a pubmed20n1443.xml 
035 |a (DE-599)NLM32892311 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Roongta, Rashmi 
245 1 0 |a Managing rheumatoid arthritis during COVID-19  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 23.10.2020 
500 |a Date Revised 23.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a The outbreak of coronavirus in the world has led to an uncertainty about treatment of patients with autoimmune disorders because of their weakened immune system coupled with immunosuppressive agents they take which predisposes them to a host of infections. Data on COVID-19 patients with underlying rheumatological diseases has been emerging mostly in the form of small case series and one global registry. From these data, it seems like our patients, although immunosuppressed, are not particularly susceptible to the coronavirus infection and if infected, do not have significantly worse outcomes than other patients. In fact, drugs like hydroxychloroquine, dexamethasone, and tocilizumab have been studied for treatment of COVID-19. However, this is only preliminary data, and since a few parts of the world are still grappling with the pandemic at its peak, we need to be equipped on how to protect and manage our immunosuppressed patients. Published evidence to guide treatment decisions are lacking and doubts regarding continuation and initiation of immunosuppressants remain. Rheumatoid arthritis (RA) is the most common immune-mediated disorder in COVID-19 patients, and in this review, we discuss how the commonly used drugs in RA alter the patients' susceptibility to this infection. The review also summarizes the recommendations from the major bodies on how to manage this disease in these times. Key Points • Patients on immunosuppressive medications are not found to be at a greatly increased risk of acquiring COVID-19 infection. • Patients doing well on a stable dose of steroid and/or Disease-Modifying Antirheumatic Drugs (DMARDs) should be allowed to continue the same unless they get infected in which case, temporary stoppage of methotrexate and leflunomide may be considered. • Initiation of high-dose steroids, DMARDs, and biologics, if the clinical situation demands so, can be done. • Maintenance biologic therapy for stable patients should be individualized by the treating physician 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Anti-Inflammatory Agents, Non-Steroidal  |6 D000894  |a therapeutic use  |6 Q000627 
653 2 |a Antirheumatic Agents  |6 D018501  |a *therapeutic use  |6 Q000627 
653 2 |a Arthritis, Rheumatoid  |6 D001172  |a *drug therapy  |6 Q000188 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Biological Products  |6 D001688  |a therapeutic use  |6 Q000627 
653 2 |a *Coronavirus Infections  |6 D018352 
653 2 |a Deprescriptions  |6 D000069340 
653 2 |a Disease Management  |6 D019468 
653 2 |a Glucocorticoids  |6 D005938  |a *therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a *Pandemics  |6 D058873 
653 2 |a *Pneumonia, Viral  |6 D011024 
653 2 |a Tumor Necrosis Factor Inhibitors  |6 D000079424  |a therapeutic use  |6 Q000627 
655 7 |a COVID-19  |2 gnd 
655 7 |a Management  |2 gnd 
655 7 |a Rheumatoid arthritis  |2 gnd 
655 7 |a Treatment  |2 gnd 
655 7 |a Anti-Inflammatory Agents, Non-Steroidal  |2 gnd 
655 7 |a Antirheumatic Agents  |2 gnd 
655 7 |a Biological Products  |2 gnd 
655 7 |a Glucocorticoids  |2 gnd 
655 7 |a Tumor Necrosis Factor Inhibitors  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Management 
689 1 2 |a Rheumatoid arthritis 
689 1 3 |a Treatment 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents, Non-Steroidal 
689 2 1 |a Antirheumatic Agents 
689 2 2 |a Biological Products 
689 2 3 |a Glucocorticoids 
689 2 4 |a Tumor Necrosis Factor Inhibitors 
689 2 |5 DE-601 
700 1 |a Ghosh, Alakendu 
773 0 8 |i in  |t Clinical rheumatology  |g Vol. 39, No. 11 (2020), p. 3237-3244  |q 39:11<3237-3244  |w (DE-601)NLM012613126  |x 1434-9949 
856 4 1 |u http://dx.doi.org/10.1007/s10067-020-05358-z  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 39  |j 2020  |e 11  |b 30  |c 10  |h 3237-3244